

# **Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Pipeline Review, H1 2018**

<https://marketpublishers.com/r/G0960DDC704EN.html>

Date: March 2018

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: G0960DDC704EN

## **Abstracts**

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Pipeline Review, H1 2018

### **SUMMARY**

According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2018'; Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA (A) Receptor Subunit Gamma 2 or GABRG2) - Gamma-aminobutyric acid receptor subunit gamma-2 is a protein encoded by the GABRG2 gene. It functions also as histamine receptor and mediates cellular responses to histamine. It functions as receptor for diazepines and various anesthetics and as ligand-gated chloride channel.

The report 'Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2018' outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit

Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III and Preclinical stages are 1, 3 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Sedation, General Anesthetic Effect, Insomnia, Anesthetic Effect, Hypertension and Status Epilepticus.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)

The report reviews Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics and enlists all their major and minor projects

The report assesses Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA (A) Receptor Subunit Gamma 2 or GABRG2) - Overview

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Companies Involved in Therapeutics Development

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Paion AG

Primex Pharmaceuticals Oy

Shire Plc

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Drug Profiles

clonazepam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EL-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LASSBio-785 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

**LASSBio-786 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**midazolam hydrochloride - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**midazolam hydrochloride - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**remimazolam - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**remimazolam - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit****Gamma 2 or GABRG2) - Dormant Products****Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit****Gamma 2 or GABRG2) - Discontinued Products****Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA (A) Receptor Subunit****Gamma 2 or GABRG2) - Product Development Milestones****Featured News & Press Releases**

Jan 15, 2018: European Medicines Agency: Defect with Buccolam oral syringes

Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Korea

Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required

Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU

Jun 05, 2017: Primex Pharmaceuticals at Euroanesthesia 2017: Next Innovation in the Management of Pediatric Sedation

Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting

Oct 05, 2016: Primex Files for Marketing Authorization for a pediatric sedative

medication

Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting

Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China

Sep 01, 2016: Primex Announces Phase II Results of ADV6209 at the 16th World Congress of Anesthesiologists

Aug 31, 2016: Primex Pharmaceuticals: Next real innovation in pediatric anesthesia since propofol

Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy

Apr 11, 2016: Paion Successfully Completes Patient Recruitment in Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy

Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA

Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance Patent for Remimazolam Besylate

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018  
Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H1 2018  
Pipeline by Paion AG, H1 2018  
Pipeline by Primex Pharmaceuticals Oy, H1 2018  
Pipeline by Shire Plc, H1 2018  
Dormant Projects, H1 2018  
Discontinued Products, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

### COMPANIES MENTIONED

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Paion AG

Primex Pharmaceuticals Oy

Shire Plc



## I would like to order

Product name: Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/G0960DDC704EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0960DDC704EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

